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In the first European study with more than 10,000 face-to-face interviews, we showed 
that 1) 92% of women either overestimated the benefits of mammography screening 
(PSA screening) by an order of magnitude or more or did not know the benefits (89% of 
men overestimated the benefits of prostate-specific antigen screening or did not know the 
benefits), and 2) frequent consultation of physicians and health pamphlets tended to 
increase the overestimates. Brenner et al. expressed unsupported skepticism about 
whether the amount of overestimation is correct. However, as Table 1 shows, other 
studies have found that people were similarly misinformed. They also wonder why we 
asked participants to estimate the benefits for women aged 40 years or older rather than 
for those aged 50 years or older, which we find odd: If estimation for age 50 years or 
older were any different from that for age 40 years or older, it would likely be even 
higher because the relative risk reductions for the older age group are higher, meaning 
that overestimation would in fact increase. 
 The second point addressed by Brenner et al. is that the true benefits of 
mammography screening are “much larger” than reported in the randomized trials and the 
Cochrane summary (6). Yet once again, they provide no evidence.  
Their third point is a fair one: In any survey, the response categories chosen can 
influence the judgments. This point is discussed in our article. We used six numerical 
categories: 0, 1, 10, 50, 100, and 200 (out of 1000). In general, midpoints in survey scales 
can serve as substitutes for "don’t know" answers (7). For this reason, we included a 
separate “don’t know” category, which was chosen by 31% of women and 30% of men. 
Not wanting to admit their lack of knowledge, some may have nonetheless chosen the 
middle categories instead. However, contrary to what Brenner et al. assumed, this 
possibility cannot explain citizens’ overestimations. The average estimates of cancer-
specific mortality reduction were 69 fewer deaths per 1000 people screened among men 
and 82 fewer deaths per 1000 people screened among women, but the midpoint of the 
response scale was lower, between 10 and 50 (i.e., the two middle categories). Choosing 
midpoints would, in fact, have decreased, not increased overestimation. 
In criticizing the response categories, Brenner et al. add that “0” is not a 
reasonable choice. Note that the US randomized prostate cancer screening trial cited in 
our article reported a cancer-specific mortality reduction of 0 in 1000 men.  
The final but again unsubstantiated suggestion is that participants might not have 
understood that the questions referred to women and men in the general population. We 
had specified this reference group clearly and used face-to-face interviews in which 
individual participants could always ask the interviewer for clarification. If 
misunderstanding was a factor, one might expect participants' education levels to 
influence overestimation. Yet there were no differences with respect to education level.  
All this evidence is inconsistent with the critique by Brenner et al. Rather than 
doubting the facts, it is time to investigate the reasons why the public is systematically 
misinformed about the benefits of prostate-specific antigen screening and mammography 
screening. 
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Table 1. Overestimation of the benefit of mammography screening by the public and by 
gynecologists  
Country Sample (reference) Main result 
Does screening reduce or prevent breast cancer? 
Germany Representative sample of 3226 
women, 50 – 69 years old, in 
2008 (1) 
56% believed that screening 
prevents breast cancer 
Germany Representative sample of 1016 
citizens, 18-92 years old, in 
2006 (2) 
46% of women and 42% of men 
believed that screening prevents 
breast cancer 
Italy,  
Switzerland,  
United 
Kingdom, 
and  
United 
States 
Representative sample of 4140 
women (3) 
81%, 65%, 69%, and 57% in Italy, 
Switzerland, United Kingdom, and 
the United States, respectively, 
believed that screening reduces or 
prevents breast cancer. 
What is the cancer-specific mortality reduction associated with screening?  
Italy, 
Switzerland, 
United 
Kingdom, 
and 
United 
States 
Representative sample of 4140 
women (3) 
94%, 91%, 96%, and 96% in Italy, 
Switzerland, United Kingdom, and 
the United States, respectively, 
estimated the benefit as 10 or more 
fewer deaths per 1000 people 
screened or did not know. 
United 
States 
145 women in their 40s with 
above-average education and 
income (4) 
Average estimate: 60 of 1000 
What does a 25% breast cancer mortality reduction mean in absolute numbers? 
Germany Representative sample of 1016 
citizens in 2006 (2) 
General lack of understanding, 
median, and modal estimate 500 of 
1000 women  
Germany 150 gynecologists participating 
in continuing education (2) 
1 of 1000 (66%);  
25 of 1000 (16%); 
100 of 1000 (3%) 
250 of 1000 (15%) 
Switzerland 15 gynecologists at a university 
hospital (5) 
1–750 of 1000 (total range);  
5–15 (majority of 10 
gynecologists)  
 
 
